Although a low plasma high-density lipoprotein cholesterol (HDL-C) level is a well-accepted
risk factor for coronary artery disease (CAD), it is unclear whether pharmacologic agents can …

OBJECTIVE: We examined both the effects of long-term bezafibrate treatment on low-density
lipoprotein (LDL) particle size in hyperlipidemic patients and the relationship between …

This study evaluated the association between changes in serum levels of high-density
lipoprotein (HDL) cholesterol that occur under bezafibrate therapy and cardiac mortality in …

抄録< jats: p>< jats: italic> Background</jats: italic>—Coronary heart disease patients with
low high-density lipoprotein cholesterol (HDL-C) levels, high triglyceride levels, or both are …

The effect of bezafibrate in the dosages 450, 900 and 1350 mg daily on serum lipoprotein
concentrations were studied in 20 subjects with primary hyperlipoproteinaemia (16 of type …

The effects of bezafibrate treatment on lipoprotein metabolism were investigated in
hypertriglyceridemic subjects. Bezafibrate, a fibric acid derivative, was administered at 200 …

Low high density lipoprotein (HDL) cholesterol, elevated triglycerides, or a combination of
both, carries an increased risk of coronary heart disease (CHD). The benefit of therapy that …

Aim: Our previous “J-BENEFIT (Japan BEzafibrate cliNical EFfectIveness and Tolerability)”
study demonstrated that bezafibrate improves blood lipid profiles and glucose control in …

Objective: To examine the atherogenic risk-reducing effect of bezafibrate and lovastatin.
Design, setting, patients, interventions: Double-blind, randomized clinical trial of male and …

Background Major randomized trials of fibrate therapy demonstrate an inverse relationship
between on-treatment high-density lipoprotein cholesterol (HDL-C) increments and clinical …